« U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), | Main | FDA Requests Seizure of More Dietary Supplements Containing Ephedrine Alkaloids »

UCB Submits Biologics License Application to FDA for New Treatment


UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease (SYS-CON Media)
BRUSSELS (Belgium) and ATLANTA, Georgia (USA), March 2, 2006 - UCB announced today the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA(TM) (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
 

©2006 FDA-News.com. All rights reserved.